2025
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research
Smith E, Phillips N, Feldman H, Borrie M, Ganesh A, Henri-Bhargava A, Desmarais P, Frank A, Badhwar A, Barlow L, Bartha R, Best S, Bethell J, Bhangu J, Black S, Bocti C, Bronskill S, Burhan A, Calon F, Camicioli R, Campbell B, Collins D, Dadar M, DeMarco M, Ducharme S, Duchesne S, Einstein G, Fisk J, Gawryluk J, Grossman L, Ismail Z, Itzhak I, Joshi M, Harrison A, Kröger E, Kumar S, Laforce R, Lanctot K, Lau M, Lee L, Masellis M, Massoud F, Mitchell S, Montero-Odasso M, Barnett K, Nygaard H, Pasternak S, Peters J, Rajah M, Robillard J, Rockwood K, Rosa-Neto P, Seitz D, Soucy J, Trenaman S, Wellington C, Zadem A, Chertkow H, Investigators C. Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research. The Journal Of Prevention Of Alzheimer's Disease 2025, 12: 100068. PMID: 39893139, PMCID: PMC12184013, DOI: 10.1016/j.tjpad.2025.100068.Peer-Reviewed Original ResearchConceptsCanadian healthcare systemStatistically significant group differencesAlzheimer's diseaseMild cognitive impairmentMild dementiaHealthcare systemStage of mild cognitive impairmentQuality evidenceSignificant group differencesMonoclonal antibody therapyTrial publicationsCerebrospinal fluid analysisCognitive impairmentCanadian ConsortiumGroup differencesPositron emission tomographyAntibody therapyImaging abnormalitiesTreatment populationClinical trialsIndividual patientsReview evidenceClinical relevanceTherapyAmyloid-related imaging abnormalities
2024
Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease
van der Flier W, Scheltens P, Feldman H, Hansson O, Sano M, Bardtrum L, Johannsen P, Jeppesen R, Hansen C, Leon T, Cummings J. Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease. Alzheimer's & Dementia 2024, 20: e088793. PMCID: PMC11713752, DOI: 10.1002/alz.088793.Peer-Reviewed Original ResearchMini-Mental State Examination scoreBaseline dataCognitive scoresClinical Dementia Rating-SumAlzheimer's diseaseApolipoprotein E4 carrier statusClinical Dementia Rating-Sum of Boxes scoresInclusion of participantsMild cognitive impairmentScreening failure rateProportion of individualsMild dementiaGeographic regionsType 2 diabetesBox scoresAD medicationsClinical characteristicsInclusion criteriaCarrier statusNorth AmericaExamination scoresClinical trial populationsPatient characteristicsCognitive impairmentSmall vessel pathology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply